Credit Suisse Cuts Price Target on Evogene (EVGN) to $10 Following 2Q

August 17, 2016 11:29 AM EDT
Get Alerts EVGN Hot Sheet
Price: $5.31 --0%

Rating Summary:
    3 Buy, 1 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Trade EVGN Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

Credit Suisse maintained an Outperform rating on Evogene Ltd (NYSE: EVGN), and cut the price target to $10.00 (from $19.00), following the company's 2Q earnings report. EVGN reported EPS of -$0.18, compared with the consensus estimates of -$0.17.

Analyst Christopher Parkinson commented, "EVGN reported 2Q16 adj. EPS of -$0.18 vs. CSe of -$0.17. Cash burn from ops in 2Q was -$2.3mm, driven primarily by a reduction in R&D payments vs. 2Q15; EVGN's cash & equivalents balance stands at $97mm, or 55% of the current market cap. EVGN continues to report a number of positive results across multiple project platforms including: corn and soybean stress tolerant genes (abiotic), novel plant targets for herbicides (collaboration with BASF), and the commencement of large-scale field trials in Central America for genes showing resistance to black sigatoka in a collaboration with Israelbased Rahan Meristem. We are raising our 2016 EPS to -$0.66 and our 2017 EPS to -$0.27. We are reducing our Target Price to $10 (from $19), based on our updated DCF analysis, assuming a 20% discount rate and a terminal growth rate of 3%."

For an analyst ratings summary and ratings history on Evogene Ltd click here. For more ratings news on Evogene Ltd click here.

Shares of Evogene Ltd closed at $6.89 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change

Related Entities

Credit Suisse, Earnings

Add Your Comment